tldrdaily.news logo
Tag

Alpine Immune Sciences

All articles tagged with #alpine immune sciences

business1 year ago

"Vertex Pharmaceuticals Acquires Kidney Disease Drug Developer for $4.9 Billion"

Vertex Pharmaceuticals announced its acquisition of Alpine Immune Sciences for $4.9 billion, causing Alpine's stock to surge by 37%. The deal is expected to close later this quarter and values Alpine stock at $65 per share, representing a 67% premium to Tuesday's close. Analysts believe Alpine's potential best-in-class treatment for IgA nephropathy, povetacicept, has the potential to lead its class due to its superior APRIL/BAFF inhibition and convenient dosing regimen. The acquisition reflects Vertex's confidence in Alpine's drug and its potential in treating autoimmune conditions. Vertex's stock also rose 1% following the announcement.

via Investor's Business Daily|
#acquisition#alpine-immune-sciences#business
business1 year ago

"Vertex Pharmaceuticals' $4.9 Billion Acquisition of Alpine Immune Sciences Targets Kidney Disease Treatment"

Vertex Pharmaceuticals Inc. is set to acquire Alpine Immune Sciences Inc. for approximately $4.9 billion, marking its largest acquisition to date. The deal will see Vertex pay $65 per share in cash for Alpine, a 67% premium over its closing price on Tuesday. The acquisition comes as Vertex looks to expand its portfolio with Alpine's immune treatments, while Alpine's stock surged 21% following reports of the potential sale.

via Bloomberg|
#acquisition#alpine-immune-sciences#biotech
business-healthcare1 year ago

"Vertex Pharmaceuticals' $4.9B Acquisition of Alpine Expands Focus to Kidney and Autoimmune Diseases"

Vertex Pharmaceuticals has announced a $4.9 billion deal to acquire Alpine Immune Sciences and its experimental drug povetacicept, aimed at treating IgA nephropathy, a kidney disease. The acquisition will expand Vertex's work in kidney and autoimmune diseases, marking a significant investment from the biotech company.

via Endpoints News|
#acquisition#alpine-immune-sciences#autoimmune-disease
business-healthcare1 year ago

"Vertex Pharmaceuticals' $4.9 Billion Bet on Kidney Disease Treatment with Alpine Immune Acquisition"

Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion in cash, gaining access to the biotech firm's treatment for IgA nephropathy, an autoimmune disease of the kidney. The deal will provide Vertex with access to Alpine's povetacicept, a mid-stage treatment for IgAN, which targets proteins contributing to autoimmune and antibody diseases. The acquisition aligns with Vertex's focus on expanding its portfolio beyond cystic fibrosis and blood disorders, and the deal is expected to close in the second quarter of 2024.

via CNBC|
#acquisition#alpine-immune-sciences#autoimmune-disease